Gastrooesophageal cancer+1
Not recruitingStudy of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer
Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer
- Disease:Gastrooesophageal cancerHER2 positive gastric cancer
- Substances:Disodium FolinateDocetaxel+4
Germany- Participants:18–64 years · 65+ years
- Substances:Disodium Folinate
- Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH









